Martin Dietrich, MD, PhD

Articles

Liquid vs Tissue Biopsies in NSCLC

August 15th 2023

Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.

Biomarker Testing in Non-Small Cell Lung Cancer

August 15th 2023

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

Exploring TROP2 Expression in Patients with NSCLC

June 16th 2023

Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, review the value of TROP2 as a target in patients with NSCLC.

Targeting HER3 in EGFR-Mutant NSCLC

June 16th 2023

Experts review data on treatment with HER3-directed agents in NSCLC for patients with EGFR mutations.

HER2-Directed Agents in NSCLC

June 9th 2023

Dr Wade Thomas Iams explains how trastuzumab deruxtecan became the standard-of-care for HER2-mutated non-small cell lung cancer.

Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer

June 9th 2023

Martin Dietrich, MD, PhD, details the molecular target CEACAM5 and its use in the treatment of patients with non-small cell lung cancer.

ADCs in Development for the Treatment of Lung Cancer

June 2nd 2023

Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.

Overview of Antibody Drug Conjugates in Lung Cancer

June 2nd 2023

Wade Thomas Iams, MD, provides an overview of antibody drug conjugates in the treatment of patients with lung cancer, including challenges and impact on clinical practice.

Emerging Concepts on the Role of Immunotherapy in NSCLC

February 20th 2023

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.

Future Perspectives in Biomarker Testing and Targeted Therapy in NSCLC

February 13th 2023

Expert oncologists look to the future of the NSCLC treatment landscape and discuss unmet needs and promising therapies.

NSCLC: Discussing Molecular Biomarkers and Treatment Decisions with Patients

February 13th 2023

Meghan J. Mooradian, MD, shares her approach to communicating with patients with NSCLC regarding treatment decisions based on molecular biomarkers.

Immunotherapy in NSCLC With Concurrent KRAS/STK11 or KRAS/KEAP-1 Mutations

February 6th 2023

Takeaways from the CheckMate 9LA, CheckMate 227, and POSEIDON trials focused on immunotherapy in non–small cell lung cancer.

Treatment Approaches for NSCLC With Concurrent KRAS/STK11 or KRAS/KEAP-1 Mutations

February 6th 2023

Meghan J. Mooradian, MD, discusses how she makes NSCLC treatment decisions based on concurrent mutations.

Clinical Insights on the Role of PD-1/PD-L1 Inhibitors in NSCLC

January 30th 2023

Martin Dietrich, MD, PhD, describes his approach to using anti-PD-1 therapies in non–small cell lung cancer.

Applying Molecular Biomarkers in Treatment Decision Making in NSCLC

January 30th 2023

An overview of the prevalence of molecular biomarkers in NSCLC and their effect on treatment decisions.

Navigating Barriers to Molecular Testing and Role of Liquid Biopsy in NSCLC

January 23rd 2023

Expert oncologists discuss barriers to molecular testing and the use of liquid biopsy in non–small cell lung cancer.

The Role of Molecular Testing In Metastatic NSCLC

January 23rd 2023

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, give an overview of the role of molecular biomarkers in the non–small cell lung cancer treatment space.

KRAS G12C–Mutated NSCLC: Real-World Implications of Novel Targeted Therapy

December 30th 2022

Closing out their review of treatment options for KRAS G12C–mutated NSCLC, expert oncologists look toward future utilization of novel targeted agents in this setting.

2L KRAS Inhibitors for Patients With KRAS G12C–Mutated NSCLC

December 30th 2022

Centering discussion on KRAS inhibitors and associated clinical trials, Martin Dietrich, MD, PhD, and Joshua Sabari, MD, detail the second-line management of KRAS G12C–mutated non–small cell lung cancer.

Non–Small Cell Lung Cancer: Selecting 1L Therapy for Patients With KRAS G12C Mutations

December 23rd 2022

Key opinion leaders identify the first-line treatment armamentarium for patients with KRAS G12C–mutated non–small cell lung cancer.